GEM ALS - GEMACBIO
Latest Information Update: 16 Jul 2016
At a glance
- Originator GEMACBIO
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in France
- 18 Jul 2005 Phase-I clinical trials in Amyotrophic lateral sclerosis in France (unspecified route)